STATUS Will Be Recruiting

To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma (iMMagine-6)

Kite Clinical Study Information Center:
Monday – Friday, 5am – 6pm PT
Email:  

Kite Clinical Study Information Center:
Monday – Friday, 5am – 6pm PT
Email:  

LAST UPDATED

October 29, 2026

Clinicaltrials.gov ID

NCT07903506

OVERVIEW

A Phase 3, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant Following Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction in Participants With Newly Diagnosed Multiple Myeloma (iMMagine-6)

PROTOCOL SUMMARY

The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM). The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel administered after quadruplet-based induction versus standard of care therapy (SOCT; quadruplet-based induction followed by autologous stem cell transplant (auto-SCT) in participants with NDMM who are eligible for auto-SCT.

View more

Participation requirements

Calendar

Age

18 years +

Condition

Sex

All

Healthy Icon

Healthy Volunteers

No

Study details

Medical Condition

Newly Diagnosed Multiple Myeloma

Gender

N/A

Date

February 2027 - March 2039

Study Type

Interventional

Study Phase

Phase 3

Product

Anitocabtagene Autoleucel, Isatuximab, Bortezomib, Lenalidomide, Dexamethasone, Fludarabine, Cyclophosphamide, Melphalan

Eligibility information

Inclusion

Inclusion criteria

  • Documented NDMM according to IMWG diagnostic criteria
  • Considered to be transplant-eligible by the investigator
  • Measurable disease at screening per IMWG, defined as any of the following:
  • 1. Serum M-protein level ≥ 1.0 g/dL; or
  • 2. Urine M-protein level ≥ 200 mg/24 hours; or
  • 3. Serum free light chain (FLC) ≥ 10 mg/dL (100 mg/L) and abnormal serum FLC ratio
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ function including hematological, renal, hepatic and cardiac with further details in protocol defined inclusion/exclusion criteria
VIEW MORE arrow
Exclusion

Exclusion criteria

  • Key Exclusion Criteria:
  • Any prior anti-multiple myeloma (MM) therapy (including B-cell maturation antigen (BCMA)-directed therapy, CAR T-cell therapy, or genetically modified cells), with the exception of protocol-specified anti-MM stabilizing therapy, radiotherapy for MM plasmacytoma(s), and palliative focal radiation
  • Central nervous system (CNS) or meningeal involvement of MM
  • Cardiac atrial or ventricular MM involvement
  • History of or active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis
  • Active malignancy (other than MM) requiring treatment for disease control within the last 24 months.
  • Prior allogeneic stem cell transplant
  • Any prior systemic treatment or radiotherapy treatment for any cancer other than MM within 24 months before randomization.
  • Live vaccine ≤ 4 weeks before randomization
  • Presence or suspicion of infection that is uncontrolled
  • History or presence of intracranial or CNS disorders or malignant CNS neoplasms
  • Females who are pregnant or breastfeeding
  • Females of childbearing potential who are not willing to use a highly effective method of contraception from the time of informed consent through the protocol-specified duration.
  • Contraindication to fludarabine, cyclophosphamide, or melphalan
  • History of allergy or hypersensitivity to any trial agent or trial drug components
  • Life expectancy < 12 weeks
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.
VIEW MORE arrow